2023年CSCO胃癌诊疗指南更新解读：转移性胃癌靶向治疗

2023-08-10 中山大学肿瘤防治中心肿瘤内科实用肿瘤杂志发表于上海

本文将对2023年指南的转移性胃癌靶向治疗部分的主要内容更新进行解读。

中文标题：

发布机构：

中山大学肿瘤防治中心肿瘤内科

发布日期：

2023-08-10

简要介绍：

中国临床肿瘤学会（Chinese Society of Clinical Oncology,CSCO）胃癌诊疗指南每年更新，融合国内外最新的临床研究进展，关注中国人群研究数据和新药在中国适应证的获批，以期临床诊疗更加符合我国胃癌国情和贴近本国临床实践，对中国临床医师及广大胃癌患者有着重要意义。胃癌靶向治疗不断取得突破，包括新靶点的识别和开发、新型靶向药物的不断涌现以及以靶向药物为基础的联合治疗策略的不断拓展等。2023年CSCO指南针对转移性胃癌靶向治疗的更新主要体现在2个方面：（1）经典靶点的新型靶向药物取得突破，代表药物为人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)的抗体偶联药物（antibody-drug conjugate,ADC）;(2)针对新靶点的靶向药物的兴起，代表药物为针对Claudin18.2的单克隆抗体。本文将对2023年指南的转移性胃癌靶向治疗部分的主要内容更新进行解读。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=42ac91c00328306e, title=2023年CSCO胃癌诊疗指南更新解读：转移性胃癌靶向治疗, enTitle=, guiderFrom=实用肿瘤杂志, authorId=0, author=, summary=本文将对2023年指南的转移性胃癌靶向治疗部分的主要内容更新进行解读。, cover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, journalId=0, articlesId=null, associationId=2585, associationName=中山大学肿瘤防治中心肿瘤内科, associationIntro=中山大学肿瘤防治中心肿瘤内科, copyright=0, guiderPublishedTime=Thu Aug 10 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<div class="row"><span id="ChDivSummary" class="abstract-text" style="color: #666666;">中国临床肿瘤学会（Chinese Society of Clinical Oncology,CSCO）胃癌诊疗指南每年更新，融合国内外最新的临床研究进展，关注中国人群研究数据和新药在中国适应证的获批，以期临床诊疗更加符合我国胃癌国情和贴近本国临床实践，对中国临床医师及广大胃癌患者有着重要意义。胃癌靶向治疗不断取得突破，包括新靶点的识别和开发、新型靶向药物的不断涌现以及以靶向药物为基础的联合治疗策略的不断拓展等。2023年CSCO指南针对转移性胃癌靶向治疗的更新主要体现在2个方面：（1）经典靶点的新型靶向药物取得突破，代表药物为人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)的抗体偶联药物（antibody-drug conjugate,ADC）;(2)针对新靶点的靶向药物的兴起，代表药物为针对Claudin18.2的单克隆抗体。本文将对2023年指南的转移性胃癌靶向治疗部分的主要内容更新进行解读。</span></div> <div class="row"> </div>, tagList=[TagDto(tagId=90181, tagName=转移性胃癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=90181, articleKeyword=转移性胃癌, articleKeywordNum=6, guiderKeywordId=90181, guiderKeyword=转移性胃癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=0, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7552, appHits=116, showAppHits=0, pcHits=1135, showPcHits=7430, likes=1, shares=11, comments=5, approvalStatus=1, publishedTime=Thu Aug 10 16:00:00 CST 2023, publishedTimeString=2023-08-10, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=6, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Aug 10 11:24:19 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Sat Jan 06 22:12:45 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023年CSCO胃癌诊疗指南更新解读：转移性胃癌靶向治疗.pdf)])

2023年CSCO胃癌诊疗指南更新解读：转移性胃癌靶向治疗.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2191937, encodeId=ec33219193e94, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:58:07 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2152876, encodeId=ce4121528e67d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:52:28 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152679, encodeId=b5c021526e96b, content=感谢老师的分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25e3556964, createdName=132689c3m54暂无昵称, createdTime=Mon Aug 14 12:44:50 CST 2023, time=2023-08-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2152120, encodeId=aeac21521201e, content=学习了，拿积分……, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36d24965953, createdName=1453e2fdm01暂无昵称, createdTime=Thu Aug 10 16:41:23 CST 2023, time=2023-08-10, status=1, ipAttribution=新疆)]
2024-03-07 中和制药东哥来自湖南省

谢谢

12 0
[GetPortalCommentsPageByObjectIdResponse(id=2191937, encodeId=ec33219193e94, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:58:07 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2152876, encodeId=ce4121528e67d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:52:28 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152679, encodeId=b5c021526e96b, content=感谢老师的分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25e3556964, createdName=132689c3m54暂无昵称, createdTime=Mon Aug 14 12:44:50 CST 2023, time=2023-08-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2152120, encodeId=aeac21521201e, content=学习了，拿积分……, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36d24965953, createdName=1453e2fdm01暂无昵称, createdTime=Thu Aug 10 16:41:23 CST 2023, time=2023-08-10, status=1, ipAttribution=新疆)]
2023-08-15 1467790cm53暂无昵称来自浙江省

学习了

33 0
[GetPortalCommentsPageByObjectIdResponse(id=2191937, encodeId=ec33219193e94, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:58:07 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2152876, encodeId=ce4121528e67d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:52:28 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152679, encodeId=b5c021526e96b, content=感谢老师的分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25e3556964, createdName=132689c3m54暂无昵称, createdTime=Mon Aug 14 12:44:50 CST 2023, time=2023-08-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2152120, encodeId=aeac21521201e, content=学习了，拿积分……, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36d24965953, createdName=1453e2fdm01暂无昵称, createdTime=Thu Aug 10 16:41:23 CST 2023, time=2023-08-10, status=1, ipAttribution=新疆)]
2023-08-14 132689c3m54暂无昵称来自河南省

感谢老师的分享

30 0
[GetPortalCommentsPageByObjectIdResponse(id=2191937, encodeId=ec33219193e94, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:58:07 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2152876, encodeId=ce4121528e67d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:52:28 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152679, encodeId=b5c021526e96b, content=感谢老师的分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25e3556964, createdName=132689c3m54暂无昵称, createdTime=Mon Aug 14 12:44:50 CST 2023, time=2023-08-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2152120, encodeId=aeac21521201e, content=学习了，拿积分……, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36d24965953, createdName=1453e2fdm01暂无昵称, createdTime=Thu Aug 10 16:41:23 CST 2023, time=2023-08-10, status=1, ipAttribution=新疆)]
2023-08-10 1453e2fdm01暂无昵称来自新疆

学习了，拿积分……

48 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化指南

2023年CSCO胃癌诊疗指南更新解读：转移性胃癌靶向治疗

相关指南

拓展阅读

科室

工具

服务